引用本文:郭红云,贾亚森(综述),冯国生(审校).埃克替尼联合放疗治疗晚期非小细胞肺癌的研究进展[J].中国临床新医学,2017,10(5):491-494.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 951次   下载 612 本文二维码信息
码上扫一扫!
分享到: 微信 更多
埃克替尼联合放疗治疗晚期非小细胞肺癌的研究进展
郭红云,贾亚森(综述),冯国生(审校)
530001 南宁,广西中医药大学研究生院(郭红云);530021 南宁,广西壮族自治区人民医院临床肿瘤中心(冯国生)
摘要:
[摘要] 研究证实埃克替尼治疗表皮生长因子受体突变的非小细胞肺癌(NSCLC)患者疗效明确,并具有放疗增敏效果。国内有大量的研究表明埃克替尼联合放疗能显著提高NSCLC患者生存时间,特别是对老年患者或脑转移患者,且不良反应较小。因此,埃克替尼联合放疗有可能成为治疗晚期NSCLC患者的有效治疗手段。现对其相关研究进展作一综述。
关键词:  非小细胞肺癌  放射疗法  埃克替尼
DOI:10.3969/j.issn.1674-3806.2017.05.29
分类号:R 734.2
基金项目:
Progress of research on Icotinib combined with radiotherapy for patients with advanced non-small-cell lung cancer
GUO Hong-yun, JIA Ya-sen, FENG Guo-sheng
Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, China
Abstract:
[Abstract] Studies confirm that Icotinib is effective in the treatment of epidermal growth factor receptor(EGFR) mutations for the patients with advanced non-small- cell lung cancer(NSCLC), and improves the curative effect of radiotherapy. A large number data of domestic studies show that Icotinib combined with radiotherapy can significantly improve the survival time for the patients, especially for the elderly patients or those with brain metastases. The combined therapy has less adverse reactions and improves the qualitiy of life, and will be an effective treatment for the patients with advanced NSCLC.
Key words:  Non-small-cell lung cancer(NSCLC)  Radiotherapy  Icotinib